Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

• OBJECTIVES: This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF). BACKGROUND: It is unknown whether angiotensin II receptor blockade is better than beta-blockade in preventing new-onset AF. METHODS: In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy. Electrocardiograms were Minnesota coded centrally, and 8,851 patients without AF by electrocardiogram or history, who were thus at risk of developing AF, were followed for 4.8 +/- 1.0 years. RESULTS: New-onset AF occurred in 150 patients randomized to losartan versus 221 to atenolol (6.8 vs. 10.1 per 1,000 person-years; relative risk 0.67, 95% confidence interval [CI] 0.55 to 0.83, p < 0.001) despite similar blood pressure reduction. Patients receiving losartan tended to stay in sinus rhythm longer (1,809 +/- 225 vs. 1,709 +/- 254 days from baseline, p = 0.057) than those receiving atenolol. Moreover, patients with new-onset AF had two-, three- and fivefold increased rates, respectively, of cardiovascular events, stroke, and hospitalization for heart failure. There were fewer composite end points (n = 31 vs. 51, hazard ratio = 0.60, 95% CI 0.38 to 0.94, p = 0.03) and strokes (n = 19 vs. 38, hazard ratio = 0.49, 95% CI 0.29 to 0.86, p = 0.01) in patients who developed new-onset AF in the losartan compared to the atenolol treatment arm of the study. Furthermore, Cox regression analysis showed that losartan (21% risk reduction) and new-onset AF both independently predicted stroke even when adjusting for traditional risk factors. CONCLUSIONS: Our novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  (hsv//swe)

MEDICAL AND HEALTH SCIENCES  (hsv//eng)

Nyckelord

MEDICIN

MEDICINE

Adrenergic beta-Antagonists/*therapeutic use

Aged

Aged

80 and over

Angiotensin II Type 1 Receptor Blockers/*therapeutic use

Atenolol/*therapeutic use

Atrial Fibrillation/*drug therapy/mortality

Cause of Death

Cerebrovascular Accident/*drug therapy/mortality

Double-Blind Method

Female

Humans

Hypertension/*drug therapy/mortality

Hypertrophy

Left Ventricular/*drug therapy/mortality

Losartan/*therapeutic use

Male

Middle Aged

Prospective Studies

Recurrence/prevention & control

Risk Factors

Survival Rate

Aged; 80 and over

Hypertrophy; Left Ventricular/*drug therapy/mortality

Stroke/*drug therapy/mortality

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)